Cigarette Smoking Effects on Liver Health

Cigarette smoke is a complex mixture of over 4 000 chemicals that reaches the liver via the bloodstream and bile, provoking a cascade of molecular and cellular disturbances. Chronic exposure disrupts lipid metabolism, promoting hepatic steatosis through increased fatty acid synthesis and impaired β-oxidation. Oxidative stress and endoplasmic reticulum dysfunction trigger inflammatory signalling and hepatocyte apoptosis, laying the groundwork for fibrosis. Over time, fibrotic scarring may progress to cirrhosis and hepatocellular carcinoma, especially when combined with metabolic comorbidities. Epidemiological studies demonstrate that both active and passive smoking elevate the incidence and severity of liver disease across diverse populations, with adolescents and patients with metabolic dysfunction particularly vulnerable. Smoking cessation can attenuate these effects, but may be accompanied by weight gain, itself a risk factor for metabolic dysfunction-associated steatotic liver disease. The global burden of smoking-related liver injury underscores the importance of integrated public health strategies and targeted interventions to mitigate progression and improve outcomes.

Research from Nature Portfolio

Recent analyses of population cohorts have linked serum cotinine—a stable nicotine metabolite—with markers of steatosis and fibrosis in adolescents. Higher cotinine levels correlate non-linearly with increased liver stiffness measurements, suggesting that even low-level smoke exposure may compromise hepatic architecture during a critical developmental window. Subgroup analyses reveal distinct inflection points beyond which fibrosis risk accelerates, supporting early prevention of both active and secondhand smoking.

Longitudinal work examining lifestyle modifications in adults has highlighted the counter-intuitive effect of smoking cessation on weight gain and steatosis. Quitting smoking was independently associated with incident fatty liver through a trajectory of rapid weight gain, while sustained weight loss and initiation of regular exercise promoted remission. Sex-specific analysis showed that exercise had a stronger protective effect in men, emphasising the need for tailored post-cessation support to prevent metabolic liver disease.

Cigarette Smoking Effects on Liver Health publication trend

The graph below shows the total number of articles in cigarette smoking effects on liver health across all publications each year (not limited to Nature Index journals).

Technical terms

Hepatic steatosis: Accumulation of fat droplets in liver cells, often the earliest manifestation of chronic liver injury.

Liver fibrosis: Excessive deposition of extracellular matrix in the liver, leading to scarring and impaired function.

Cotinine: A primary metabolite of nicotine used to quantify tobacco exposure in biological samples.

Liver Stiffness Measurement (LSM): A non-invasive ultrasound-based assessment of liver hardness, reflecting fibrotic changes.

MASLD: Metabolic dysfunction-associated steatotic liver disease, the contemporary term for non-alcoholic fatty liver disease linked to metabolic risk factors.

References

1. Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD. Hepatology Communications (2023).
2. Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy. Cells (2025).
3. Association between serum cotinine and hepatic steatosis and liver fibrosis in adolescent: a population-based study in the United States. Scientific Reports (2024).
4. Active Smoking, Passive Smoking, and Risk of Nonalcoholic Fatty Liver Disease (NAFLD): A Population-Based Study in China. Journal of Epidemiology (2013).
5. Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. Scientific Reports (2020).
6. Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease. Journal of Clinical Medicine (2023).